Breast Journal最新文献

Objectives: Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological features of skin manifestations in IGM.

Methods: We retrospectively analyzed 138 women with biopsy-proven IGM who underwent breast and skin ultrasonography between 2023 and 2024. Clinical cutaneous findings were documented, and 14 patients with visible skin lesions underwent additional punch biopsy for histopathological evaluation. Sonographic and clinical features were stratified according to symptom duration (0–3, 4–6, 7–9, and ≥ 10 weeks).

Results: Cutaneous lesions were identified in 84/138 patients (60.9%). Sonographic findings followed a sequential distribution: fibrous echogenicity loss in early disease (11/14, 78.6%), vacuolar structures at 4–6 weeks (11/19, 57.9%), dermo-subcutaneous blurring at 7–9 weeks (9/34, 26.5%), and advanced features such as fistula formation (11/17, 64.7%) and dermo-subcutaneous disruption (11/17, 64.7%) beyond 10 weeks. Clinical findings paralleled imaging, with erythema and papulopustular lesions predominating early (13/14, 92.9%), erythema nodosum peaking at 4–6 weeks (7/19, 36.8%), and ulceration and fistula formation emerging after ≥ 7 weeks (11/17, 64.7% at ≥ 10 weeks). Histopathological analysis of 14 skin biopsies demonstrated nonspecific inflammatory changes without granuloma formation.

Conclusions: IGM demonstrates sequential sonographic and clinical cutaneous patterns associated with symptom duration. Early erythematous and papulopustular changes progress to ulceration and fistula formation in prolonged disease. Although supportive in suggesting cutaneous involvement, these features are not diagnostic, and histopathological confirmation remains essential. Prospective studies are warranted to further define the clinical and histological course of cutaneous changes in IGM.

Y. Bozkaya, F. Oz Puyan, and B. Bimboga, “Primary bilateral breast lymphoma in an elder male patient,” The Breast Journal 25, no. 5 (2019): 1008-1009, https://doi.org/10.1111/tbj.13394.

In the article titled “Primary bilateral breast lymphoma in an elder male patient,” there was a spelling error in author Busem Binboga’s name in the author list, where Busem Bimboga should have read Busem Binboga. The corrected author list and affiliation list should be as follows:

Yakup Bozkaya¹, Fulya Oz Puyan², Busem Binboga²

¹Clinic of Medical Oncology, Edirne State Hospital, Edirne, Turkey

²Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey

We apologize for this error.

H. Li, Q. Niu, C. Jia, et al., “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” The Breast Journal 2025 (2025): 6070736, https://doi.org/10.1155/tbj/6070736.

In the article titled “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” there was an error in affiliations 1 and 2 order. The corrected author list and affiliation list should be as follows:

Hui Li^1,2, Qinghua Niu¹, Chao Jia¹, Gaoxiang Fan¹, Long Liu¹, Gang Li¹, Penglin Zou¹, Rong Wu¹, Lianfang Du¹, Jing Wang³, and Qiusheng Shi¹

¹Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

²Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, China

³Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

We apologize for this error.

L. J. van Zeelst, R. Derksen, C. H. W. Wijers, et al., “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators,” The Breast Journal 2022 (2022): 1863519, https://doi.org/10.1155/2022/1863519.

In the article titled “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators” there were errors in Figure 1 and Table 1.

In Figure 1 legends, inpatient mastectomy and outpatient mastectomy were attributed to the wrong colour. The corrected Figure 1 is shown below.

In Table 1, values in the polypharmacy rows were incorrect. The corrected Table 1 is shown below.

We apologize for this error.

Purpose: This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in evaluating breast lesions with type 2 dynamic curves.

Materials and Methods: We retrospectively reviewed 181 breast lesions with type 2 dynamic curves in 181 consecutive patients who underwent 3-Tesla (3-T) magnetic resonance imaging (MRI). Trained radiologists assessed the morphological features of the lesions on dynamic contrast-enhanced (DCE) MRI, DWI, and T2WI using BI-RADS lexicon descriptors and measured the apparent diffusion coefficient (ADC). Statistical analysis was performed to compare variables in lesion type groups (mass-like group vs. nonmass-like group). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test, with statistical significance at p < 0.05.

Results: In mass-like lesions, all morphological parameters significantly distinguished benign from malignant lesions on DCE, DWI, and T2WI (all p < 0.05). ADC values also showed significant differences (p < 0.05). The combined approach (DCE + DWI + T2WI) yielded the highest AUC (0.895), significantly outperforming the individual methods (all p < 0.05). In nonmass-like lesions, no parameter significantly predicted malignancy (all p > 0.05).

Conclusion: The addition of DWI and T2WI, interpreted using the BI-RADS lexicon descriptors, enhances the differential diagnosis of breast lesions with type 2 dynamic curves.

Purpose: The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor–positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.

Materials and Methods: We evaluated 879 breast cancer cases diagnosed from January 2018–March 2022 within a major health system in Hawaii, 600 of which received Oncotype DX recurrence scores to provide prognostic and therapy-predictive information based on NCCN guidelines. Linear regression with both univariable (unadjusted) and multivariable (adjusted for all other variables) models was run on the 600 breast cancer cases that received Oncotype DX recurrence scores. The predictor variables were age at diagnosis, race, tumor size, ER/PR status, and histology.

Results: On multivariable analysis, we found statically significant differences in Oncotype DX recurrence scores according to age (60–69 vs. 18–49, p = 0.01), ER/PR status (PR-positive vs. PR-negative, p < 0.0001), histology (other vs. ductal, p = 0.004), and tumor size (2–5 cm vs. 0-1 cm, p = 0.0003). We found no significant differences in Oncotype DX recurrence scores according to race/ethnicity.

Conclusion: Our findings indicate that Oncotype DX recurrence scores are not variable according to race/ethnicity, highlighting the need for further research to understand the known disparities in breast cancer outcomes among different racial/ethnic groups. Our study supports the correlation between Oncotype DX recurrence scores and other factors and aligns with established prognostic trends for these variables in a diverse population. This study supports the applicability for the Oncotype DX test in a diverse breast cancer population of Hawaii.